Astellas Logo (Astellas Logo 01)
Astagraf Xl Capsule, Coated, Extended Release
Product Images NDC 0469-0687
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Astagraf Xl (NDC 0469-0687). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Astellas Pharma Us, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Astellas Logo (Astellas Logo 02)
Astellas Logo (Astellas Logo 03)
Image 01
Image 02
Image 03 01
Tacrolimus Structural Formula (Image 04)
Figure 1: Effect Of Co-administered Drugs On The Pharmacokinetics Of Tacrolimus (when Given As Astagraf Xl®) (Image 05)
Description: This text appears to show a comparison of the effects of drugs on the pharmacokinetics of Tacrolimus, specifically in relation to Astagraf XL. The drugs compared are ketoconazole and rifampin, with different dosing regimens. The text mentions Cmax and AUC values, as well as a geometric mean ratio and 90% confidence interval. However, due to the fragmented nature of the text, it is difficult to provide a more detailed description.*
Figure 2: Effect Of Co-administered Drugs On The Pharmacokinetics Of Tacrolimus (when Given As Immediate-release Tacrolimus) (Image 06)
This is a report on the pharmacokinetics of co-administered drugs with tacrolimus. The report includes information on the Cmax and AUC of several drugs including telapravi, boceprevir, magnesium hydroxide, voriconazole, and posaconazole. The report also provides Geometric Mean Ratio of Test to Reference and 90% CI for tacrolimus immediate release alone and with co-administered drugs.*
Astagraf Xl (tacrolimus Extended-release Capsules) 0.5 mg Label (Image 10)
This appears to be a medication label for the drug Astagraf XL® (tacrolimus extended-release capsules) which is available for daily use with a dosage warning. The label also mentions a Varnish-free area requirement for printing the LOT, EXP, and something that appears to be "Proatatsspm Soa Fcksga". There are 30 capsules in the container.*
Astagraf Xl (tacrolimus Extended-release Capsules) 1 mg Label (Image 11)
This is a label or packaging description for the pharmaceutical product Astagraf XL. It describes the product as "tacrolimus extended-release capsules" to be used for the printing of lot, EXP and serialization information. The dosage and the form of the drug are provided. The label also indicates the number of capsules per package.*
Astagraf Xl (tacrolimus Extended-release Capsules) 5 mg Label (Image 12)
This text appears to be a label of medication called Astagraf XL, which comes in the form of extended-release capsules that contain tacrolimus. The label specifies some important information such as the dosage regimen (once-daily), prescriptions restrictions (RxOnly), and serialization information. However, the text does not provide any further details regarding the medication's indications, efficacy, safety or side effects.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
